Listeria monocytogenes is an important cause of bacteremia and meningitis in neonates and immunocompromised patients (7, 10, 12, 17, 20, 22) . Although penicillin G and ampicillin (with or without an aminoglycoside) are considered the drugs of choice for the treatment of Listeria infection, there is a need for alternative drugs in cases of penicillin-allergic patients and in therapeutic failures (2, 30).
I,mipenem was evaluated for its in vitro and in vivo activities aloie and in combination with gentamicin against a cdinial isolate of Listeria monocytogenes, and the results were compared with the activities of ampicillin with and without gentamicin. In vitro, the MBC of imipenem was fourfold less than that of ampicillin. Checkerboard determinations of the MBC& exhibited a synergistic response for imipenemgen,ta,micin but an indifferent response for amnpicillin-gentamicin. In vivo studies with experim%'ntal bacteremia an4 menipgitis due to L. monocytogenes in newborn rats revealed that both 'imipenem-cilastatin and ampicillin ot a dose of 50 mg/kg produced excellent bactericidal titers in serum. Overall mortality rates were not significa4tly different among four groups of animals receiving imipenem-cilastatii!, imipenem-cilastatingentamicin, aotpicillin or am,picillin-gentamicin. However, imipenem-cilastatin alone or in combination with gentamicin was si'gnificantly less effective than ampicillin or ampicillin-gentankicin, as judged by the rapidity of clearance of bacteria from blood, liver, and sple,en. These findings suggest thnt imipenem-cilastatin and imipenem-cilastatin-gentamicin may not be suitable alternativeS for the treatment of listeriosis.
Listeria monocytogenes is an important cause of bacteremia and meningitis in neonates and immunocompromised patients (7, 10, 12, 17, 20, 22) . Although penicillin G and ampicillin (with or without an aminoglycoside) are considered the drugs of choice for the treatment of Listeria infection, there is a need for alternative drugs in cases of penicillin-allergic patients and in therapeutic failures (2, 30) .
'Imipenem (N-formimidoyl thienamycin), unlike newer cephalosporins, appears to be a promising candidate because of its excellent in vitro activity against L. monocytogenes with an MIC for 90% of strains tested of s 0.12 ,ug/ml (9, 13, 21, 31) . In addition, combinations of imipenem-gentamicin have been shown to be synergistic in vitro against L. monocytogenes (9). However, in vivo evaluation of imipenem against L. monocytogenes has not been reported. The present study therefore was performed to examine the in vitro and in vivo activities of imipenem and imipenemgentamicin in comparison with ampicillin and ampicillingentamicin against L. monocytogenes.
MATERIALS AND METHODS
Organism. A clinical strain of L. monocytogenes (strain LM2) that was isolated from the blood of an infant with sepsis was used in the in vitro and in vivo experiments.
In vitro studies. MICs and MBCs were measured in Todd-Hewitt broth (Difco Laboratories, Detroit, Mich.) by the standard macrobroth dilution method (29 when the index was greater than 4, the combination was considered antagonistic; when the index was 0.5 to 4, the combination was considered indifferent.
In vivo studies. Outbred, pathogen-free, pregnant SpragueDawley rats with timed conception were purchased from Charles River Breeding Laboratories, Inc., Wilmington, Mass., and gave birth in a vivarium 5 to 7 days after arrival.
A total of 89 pups from eight litters were used for this study. At 5 days of age, all members of each litter were inoculated intraperitoneally with 3.1 x 107 to 5.3 x 107 CFU of L. monocytogenes in a volume of 0.05 ml. Our preliminary studies have shown that this inoculum of L. monocytogenes produces bacteremia (with or without meningitis) in 100% of the animals within 18 h of inoculation. At 18 h after inoculation and daily thereafter for 4 days, 0.1 ml of blood and 0.01 ml of cerebrospinal fluid (CSF) were obtained as previously described for quantitative cultures (15, 16) . Because blood and CSF samples were obtained at 8 a.m., more than 12 h after the last dose of antibiotics was administered, no attempt was made to inactivate any residual antibiotics in In ViVQ findings. Eighteen hours after inoculation and just before therapy, all 89 rats were bacteremic, and the bacterial counts in blood were not significantly different among the six treatment groups (Table 2) .
In Table 2 the overall mortality and bacterial clearance from blood among the six treatment groups are compared. All animals receiving saline (control) or gantamicin died within 3 days of therapy. Otherwise, the mortality rates among the remaining four treatment groups were not significantly different.
The bacterial clearance from blood of animals in the six treatment groups was compared by determining the bacterial counts of animals with positive blood cultures at 1, 2, and 3 days of completed therapy ( Table 2 ). In every group, the number of animals available for these observations decreased with time. Bacterial counts in blood increased in animals receiving saline or gentamicin, while treatment with the other four antibiotic regimens enhanced bacterial clearance from the blood of surviving animals and was able to eradicate L. monocytogenes completely from blood after 3 days of therapy. Of note, the incidence of bacteremia during therapy was significantly different among the latter four treatment regimens. Significantly more (P < 0.05) animals receiving imipenem-cilastatin were bacteremic than those receiving amipicillin at the end of 1 and 2 days of therapy. Also, the incidence of bacteremia was significantly greater (P < 0.05) in animals receiving imipenem-cilastatin or imipenem-cilastatin-gentamicin than in those receiving ampicillin-gentamicin at the end of 1 day of therapy (Table   2 ).
Only four animals (two animals each from the ampicillin and the imipenem-cilastatin-gentamicin treatment groups) had positive CSF cultures before therapy, and the bacterial clearance from CSF could not be properly assessed. Instead, the six treatment groups were compared for their efficacy in preventing the development of meningitis during therapy. Among the 85 bacteremic animals without meningitis before therapy, 44 survived beyond 1 day of therapy and were available for this comparison. L. monocytogenes meningitis was noted only in animals receiving imipenem-cilastatin (1 of 11 or 9%), gentamicin (2 of 7 or 29%), and saline (1 of 3 or 33%). In contrast, none of the 23 animals developed meningitis in the ampicillin, imipenem-cilastatin-gentamicin, and ampicillin-gentamicin treatment groups. These differences among the six treatment groups were not statistically significant.
In Table 3 comparisons of the bacterial counts in liver and spleen of 24 surviving animals on day 4 of therapy are shown. At this time, all survivors were free of bacteremia (Table 2) . However, only seven spleen specimens (two from the ampicillin and five from the ampicillin-gentamicin treatment groups) were free of L. monocytogenes. Overall, the bacterial counts in liver and spleen were significantly greater (P < 0.02) in rats receiving imipenem-cilastatin or imipenemcilastatin-gentamicin than in those receiving ampicillin or ampicillin-gentamicin.
Bactericidal titers (ranges) in serum at 1 to 2 h after subcutaneous injection of the various antimicrobial agents were, as expected from drug levels in serum which far exceeded the respective MBCs ( b Numbers in parentheses indicate the number of animals positive for culture after completion of treatment day/the number of animals positive for culture before therapy and available for subsequent examination of blood cultures.
C The incidence of bacteremia after 1 and 2 days of therapy was significantly less (X2 = 5.40 and 4.17, respectively; P < 0.05) with ampicillin than with imipenemcilastatin. d The incidence of bacteremia after 1 day of therapy was significantly less with ampicillin-gentamicin than with imipenem-cilastatin (X2 = 6.45; P < 0.02) or imipenem-cilastatin-gentamicin (X2 = 4.37; P < 0.05). ' NA, No survivors available.
DISCUSSION
The optimal antibiotic therapy for L. monocytogenes infection, particularly in immunocompromised patients, has not been clearly established (7, 20) . Meningitis remains the most common clinical form of L. monocytogenes infections (5, 6, 17) , and for such a condition, bactericidal antimicrobial regimens are theoretically desirable because of the ineffi- 6.09 ± 1.14 (5) Ampicillin 4.71 ± 0.50c (6) 3.37 ± 1.29' (6)d
Imipenem-cilastatin-6.32 ± 0.38 (4) 6.00 ± 1.21 (4) gentamicin Ampicillin-gentamicin 4.40 ± 0.38e (9) 3.02 ± 1.29e (9)d a Values are expressed as mean + standard deviation (log 10 CFU/gm) b Numbers in parentheses indicate the number of animals from which bacterial counts were derived.
c Significantly less (P < 0.02) than results with imipenem-cilastatin or imipenem-cilastatin-gentamicin.
d Spleens from two animals receiving ampicillin and five animals receiving ampicillin-gentamicin had negative cultures. For calculation of bacterial counts, these specimens were considered to contain 10? CFU/g, based on the average weight of the spleen (0.1 g).
eSignificantly less (P < 0.01) than results with imipenem-cilastatin or imipenem-cilastatin-gentamicin. ciency of opsonization within the CSF (27, 28) . Penicillin and ampicillin, although not uniformly bactericidal against L. monocytogenes (19, 25) , are almost always efficacious in the treatment of L. monocytogenes infections (22, 32) . However, in penicillin-allergic patients, a suitable alternative agent has not been clearly established. Tetracycline, chloramphenicol, and erythromycin have been suggested, but they are bacteriostatic against L. monocytogenes, and potential antagonism exists with the use of tetracycline and chloramphenicol (11, 31) . Trimethoprim-sulfamethoxazole has been shown to be bactericidal in vitro against L. monocytogenes (33) , but its in vivo activity has not been reported.
Imipenem appears to be a promising candidate because of its excellent activity in vitro against L. monocytogenes (9, 13, 21, 31). In addition, Eliopoulos and Moellering have shown a synergistic killing effect in vitro by the addition of gentamicin to imipenem (9) , which similar to the effect seen with ampicillin-gentamicin combinations (11, 19, 26) . The present study therefore was performed to evaluate and compare the in vivo efficacies of imipenem and ampicillin alone and in combination with gentamicin against L. monocytogenes.
In vitro, both imipenem and ampicillin were bactericidal against a L. monocytogenes strain, but the MBC of imipenem was fourfold less than that of ampicillin. The addition of gentamicin to imipenem yielded a synergistic effect, while ampicillin-gentamicin combinations resulted in an indifferent response. In vivo studies with an experimental bacteremia and meningitis due to L. monocytogenes in newborn rats revealed that mortality rates were not signifi-291 VOL. 29, 1986 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from cantly different among animals receiving imipenem-cilastatin or ampicillin, with or without gentamicin. However, imipenem-cilastatin alone and in combination with gentamicin were, despite their excellent bactericidal titers in serum, less efficacious than ampicillin or ampicillin-gentamicin. This was shown by (i) a significantly greater incidence of bacteremia after 1 and 2 days of therapy in rats receiving imipenem-cilastatin than in those receiving ampicillin, (ii) the development of meningitis in one animal during therapy with imipenem-cilastatin, (iii) a significantly greater number of animals receiving imipenem-cilatatin or imipenemcilastatin-gentamicin being bacteremic after 1 day of therapy than those receiving ampicillin-gentamicin, and (iv) significantly greater bacterial counts in livers and spleens of rats receiving imipenem-cilastatin or imipenem-cilastatingentamicin than of those receiving ampicillin or ampicillingentamicin. The reasons for this in vitro and in vivo discrepancy of imipenem activity are not clear. This discrepancy was not due to different pharmacokinetics of imipenem in newborn rats. As shown previously (Table 1) , subcutaneous administration of imipenem at a dose of 50 mg/kg resulted in mean levels in serum of approximately 100 and 2 times the MBC, respectively, at 1 to 2 and 6 to 7 h, which is similar to the levels obtained with ampicillin. The findings of this study are also quite different from my previous experiences with imipenem against other microorganisms (14, 15) . I and others have shown that imipenem-cilastatin is very effective in the treatment of experimental bacteremia and meningitis due to Escherichia coli and group B streptococci (14, 15, 24) . Because L. monocotogenes is a facultative intracellular parasite (4), the limited efficacy with imipenem may reflect the inability of this agent to penetrate phagocytic cells and kill intracellular bacteria. Additional studies are needed to confirm this hypothesis.
Another intriguing finding was the failure to eradicate L. monocytogenes from the reticuloendothelial systems (liver and spleen) of infected animals by all antimicrobial regimens, even at a time when all blood cultures became negative. Only approximately half of the spleen samples obtained from rats receiving ampicillin or ampicillingentamicin were culture negative. Whether bacterial persistence in liver and spleen may contribute to the impaired in vivo bactericidal activities of certain antibiotics (e.g., imipenem-cilastatin) against L. monocytogenes remains to be determined.
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